Federal Circuit: Pink Hip Implants Are Functional, Cannot Be Protected as Trade Dress

by Dennis Crouch

The Federal Circuit has affirmed the Trademark Trial and Appeal Board (TTAB) cancellation of CeramTec's trademark registrations for the pink color of its ceramic hip implants, and also providing an important analysis of functionality doctrine and its intersection with expired utility patents. CeramTec GmbH v. CoorsTek Bioceramics LLC, No. 2023-1502 (Fed. Cir. Jan. 3, 2024).  The cautionary outcome here is unsubstantiated statements in the utility patent left the patentee unable to later claim trade dress protection for the distinctive feature.  Patent attorneys should consider a trade dress discussion with their clients prior to filing a utility application that covers potentially distinctive trade dress. I discussed the case while it was pending. See Dennis Crouch, Pink Ceramic Hip Implants: When Functionality Trumps Trade Dress, Patently-O (October 2024).


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Patent Term Adjustments Cut by Applicant Delays: A 23,000 Year Impact

by Dennis Crouch

The Patent Term Adjustment (PTA) statute was designed to ensure patent terms aren't unfairly shortened by USPTO delays during prosecution. 35 U.S.C. § 154(b). The basic framework provides day-for-day extension of patent term to account for certain examination delays, such as when the USPTO takes more than 14 months to issue a first office action or more than 4 months to respond to an applicant's reply.

But PTA is a two-way street. The statute also penalizes applicants who fail to "engage in reasonable efforts to conclude processing or examination." 35 U.S.C. § 154(b)(2)(C). The most common applicant delay comes from taking more than three months to respond to an office action. See 37 C.F.R. § 1.704(b).


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Not Quite Teaching Away: Federal Circuit Clarifies Evidence Needed to Defeat Motivation to Combine

by Dennis Crouch

In a recent non-precedential decision, the Federal Circuit provided an interesting analysis on how to evaluate evidence both supporting and undermining motivation to combine references in obviousness challenges. Laboratory Corporation of America Holdings v. Ravgen, Inc., No. 2023-1342, 2023-1345 (Fed. Cir. Jan. 6, 2025).


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Ripe for Review: Digital Access to a Banana taped to the Wall

by Dennis Crouch

Let me peel back the layers of this slippery copyright dispute that has the art world going bananas. In Morford v. Cattelan, No. 23-12263 (11th Cir. 2024), the Eleventh Circuit confronted the question of whether an artist can claim copyright protection over the concept of taping a banana to a wall. The appellate court sided with the accused famous artist, Morford continues to pursue his copyright action in a newly filed petition for writ of certiorari to the Supreme Court.

(more…)

Patents as Product Liability Admissions: A Cert Petition Highlights Novel Use of Patent Filings in Whistleblower Case

by Dennis Crouch

A fascinating cert petition filed last week (Peterson v. Minerva Surgical) uses Minerva’s patents in an innovative way — attempting to use the company’s patent filings as evidence of prior knowledge of product safety issues. The petition, filed by former Minerva Surgical area sales director Dan Peterson, argues that the company’s patent application for an improved surgical device directly contradicted testimony it later gave in whistleblower retaliation arbitration proceedings.

According to the petition, in January 2017, Minerva filed Patent Application No. 15/418,635 seeking protection for a modified endometrial ablation device. The application disclosed that the original design had a defect that could “plug” uterine perforations, potentially leading to serious patient injuries. The USPTO ultimately granted the patent (No. 10,213,151) in February 2019, with claims explicitly discussing how the new design solved these safety issues. (more…)

Federal Circuit Internal Debate over Reversal versus Vacatur

by Dennis Crouch

Yesterday, the Federal Circuit issued a divided opinion in Honeywell International Inc. v. 3G Licensing, S.A., No. 2023-1354 (Fed. Cir. Jan. 2, 2025), highlighting key disagreements about the proper role of appellate courts in reviewing Patent Trial and Appeal Board (PTAB) decisions.  The case appears to also foreshadow an internal fight over the exclusion of expert testimony that is currently pending en banc in EcoFactor v. Google.

The case centers on the validity of a patent related to encoding data in cellular communications, specifically focusing on methods for protecting important data bits from transmission errors.  Patent No. 7,319,718.  Writing for the majority, Judge Dyk reversed the PTAB's holding that the claims were not proven obvious. Judge Stoll write in dissent, arguing the majority improperly stepped into the role of fact-finder rather than acting as an appellate tribunal.  To be clear, Judge Stoll was no fan of the PTAB's opinion, but would have vacated and remanded for further factual development on the question of obviousness rather than entirely flipping the decision via reversal.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Supreme Court Preview: Will “Skinny Labels” Get a Weight Check?

by Dennis Crouch

The Supreme Court will soon be asked to weigh in on the the skinny-label debate -- particularly the question of how much a generic drug manufacturers can say about their products without inducing patent infringement? The case is Hikma v. Amarin.

It is very common for a drug to follow the following innovation-patent pathway:

  1. First the composition is discovered and patented along with a particular therapeutic use.
  2. Later a more effective treatment regimen is discovered and patented.

Once the first set of patents expire, generic manufactures should be permitted to begin marketing the drug -- except for uses still patented.  But, this gets tricky.  We know that there will be a very $trong incentive for insurance companies, doctors, and patients to use the cheaper generic drug for the still-patented treatment regime.  The question is whether the generic manufacture can be blamed for inducing this infringement.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Patent Grants for 2024

by Dennis Crouch

For decades the USPTO has issued patents each and every Tuesday -- with data being released typically at 12:01 a.m. Eastern time.  Today's release wraps up 2024 and almost breaks a record with 7,499 utility patents issued -- the second most ever in any given week.  (The #1 spot is held by 7669 utility patents issued on October 3, 2023).  The total UTL patents issued has been rising for the past several years but are still below the 2019 high point at over 350,000.

As you look at the chart above, the 2024 patent count numbers are a bit skewed upward because of a calendaring quirk. While most years have 52 Tuesdays, 2024 has 53 Tuesdays. This extra Tuesday means the USPTO has one additional patent issue day compared to a typical year, which represents roughly a 2% increase in opportunities for patent grants over the calendar year.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Federal Circuit Affirms Invalidity of Purdue’s OxyContin Patents

by Dennis Crouch

The Federal Circuit recently affirmed the invalidity of several Purdue Pharma patents related to abuse-deterrent and low-impurity formulations of OxyContin. Purdue Pharma L.P. v. Accord Healthcare, Inc., No. 2023-1953 (Fed. Cir. Dec. 30, 2024).  Although non-precedential, the appeal addresses three significant legal questions in obviousness jurisprudence: (1) The consideration given to discovering the source of a previously known problem under Eibel Process Co. v. Minnesota & Ontario Paper Co. (1923); and (2) how inherent properties of prior art compositions factor into obviousness analysis when combining multiple references similar to the Cytiva decision from earlier in 2024.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Voluntary Dismissals and Attorney Fees

by Dennis Crouch

The Copyright Act and the Patent Act each include an attorney fee provision — permitting the district court to award “a reasonable attorney’s fee to the prevailing party.”  Because of similarities in the provisions, they tend to be interpreted together — at least with regard to what qualifies as a “prevailing party” under the statute.  (Unlike in copyright law, the patent law limits fees to “exceptional case[s]”).

On the Copyright side, there is a growing circuit split on the issue of whether defendants can recover attorney’s fees after a plaintiff voluntarily dismisses under Rule 41(a)(1).   That rule permits for voluntary dismissal and does not require a court order.  Affordable Aerial Photography, Inc. v. Property Matters USA, LLC, 108 F.4th 1358 (11th Cir. 2024), the 11th Circuit held that “some judicial action rejecting or rebuffing a plaintiff’s claim is necessary to endow a defendant with prevailing party status.”  In a parallel decision, the 11th Circuit clarified that a plainttif’s voluntary dismissal does not create a prevailing party status even if made “with prejudice.” Affordable Aerial Photography, Inc. v. Reyes, No. 23-12051, 2024 WL 4024619 (11th Cir. Sep. 3, 2024).

The Federal Circuit has developed a body of law holding that voluntary dismissals with prejudice can support prevailing party status and fee awards in patent cases. See O.F. Mossberg & Sons, Inc. v. Timney Triggers, LLC, 955 F.3d 990 (Fed. Cir. 2020). However, the Federal Circuit generally denies prevailing party status after Rule 41(a)(1) dismissals without prejudice.  The Ninth Circuit approach looks to the general question of preclusion – asking whether the plaintiff is “judicially precluded from refiling the claim.”  If so, then the defendant qualifies as the prevailing party. Cadkin v. Loose, 569 F.3d 1142 (9th Cir. 2009). So, we have something of a split here between the various circuits. (more…)

Trade Secret Protection in the Digital Age: When Does Web Scraping Cross the Line?

by Dennis Crouch

I'm following a new cert petition that asks the Supreme Court to examine when web scraping becomes an improper means of obtaining trade secret information under the the DTSA. I regularly use web scraping for academic research, and so this case caught my attention for more than just the intellectual property curiosity.

The specific question presented to the Supreme Court is "whether an action that is not unlawful under the federal Defend Trade Secrets Act ('DTSA') when performed manually by a human (or humans) is unlawful when performed by a computer robot." This framing presents a parallel to the seminal 1970 aerial photography case of E. I. duPont deNemours & Co. v. Christopher, 431 F.2d 1012 (5th Cir. 1970).


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

TikTok – A First Look at the Briefs

Briefs are trickling in for the Supreme Court’s fast-paced battle over the upcoming TikTok ban.   The outcome of TikTok v. Garland will likely be a watershed moment for free speech in the digital age — especially with respect to non-US media.  This post walks through the six amicus briefs all filed early.  Three support TikTok and its content creator co-petitioners; and three agree with the appellate court and U.S. government that the ban is appropriate.

As background: TikTok has over 170 million U.S. users but is ultimately owned by Chinese company ByteDance, which under Chinese law must share data and comply with Chinese Communist Party directives. After years of bipartisan concern about TikTok’s data collection practices and potential for content manipulation, Congress passed the Protecting Americans from Foreign Adversary Controlled Applications Act (PAFACAA) in April 2024 with strong support from both parties, and President Biden signed it into law. The Act effectively requires ByteDance to sell TikTok to non-Chinese owners by January 19, 2025, or face a ban on U.S. operations. TikTok and several content creators immediately challenged the law as violating the First Amendment, but the D.C. Circuit upheld the ban in December 2024, finding that even if strict scrutiny applied, the government’s national security interests justified the restriction. With the divestiture deadline looming, the Supreme Court took the extraordinary step of granting immediate review and scheduling arguments for January 10, 2025, just nine days before the law would take effect. The case presents novel questions about how traditional First Amendment doctrines apply to social media platforms controlled by potentially hostile foreign powers and tests the limits of Congress’s authority to restrict foreign ownership of communications infrastructure. (more…)

Some numbers from this week

by Dennis Crouch:

  • On December 24, 2026 2024, the USPTO issued 6,920 utility patents and 800 design patents. The vast majority of utility patents are published prior to issuance - this week the numbers were 94%.
  • The utility allowance rate was 86% for the week - calculated as the number patented divided by the number disposed of (patented / (patented + abandoned)). 90% of abandoned cases were - as you might expect - for failure to respond to an office action. A distant #2 was failure to pay the issue fee.
  • For the week, patent applications in semiconductor and display technologies (AU groups 2620, 2820) show extremely high allowance rates of 97-98%. In contrast, business methods, GUI, and AI-modeling patent applications (AU groups 3680, 2140, 2120) face much lower allowance rates around 59-62%, reflecting stricter scrutiny in these software and "abstract-idea" focused domains.

To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Non-Patent IP Cases at the Supreme Court: December 2024 Update

by Dennis Crouch

I recently posted about pending patent cases before the Supreme Court, this post goes into the non-patent intellectual property cases:

On December 11, 2024, the Court heard arguments in Dewberry Group, Inc. v. Dewberry Engineers Inc., No. 23-900, addressing profit calculations for trademark misappropriation under Section 35(a) of the Lanham Act, 15 U.S.C. § 1117(a). This is the only IP case that has been granted certiorari this term. The dispute stems from a $43 million disgorgement award based on profits earned by companies affiliated with, but legally distinct from, the defendant. The central question is whether courts can consider affiliate revenues without first “piercing the corporate veil.”

During oral argument, the Justices focused heavily on corporate law fundamentals. Several appeared skeptical of the respondent’s argument that courts can treat affiliate profits as evidence of a defendant’s “true financial gain” without disregarding corporate separateness. The Court’s ultimate resolution could significantly impact how companies structure their IP holdings and licensing arrangements between related entities.

Two interrelated petitions examine internet service provider liability for copyright infringement. In Cox Communications, Inc. v. Sony Music Entertainment, No. 24-171, and Sony Music Entertainment v. Cox Communications, Inc., No. 24-181, the Court confronts important questions about secondary liability following a $1 billion jury verdict. The Cox petition challenges the Fourth Circuit’s holding that an ISP “materially contributes” to infringement merely by continuing service to known infringing subscribers. This arguably conflicts with decisions requiring either active promotion of infringement (Second and Tenth Circuits) or at least failure to implement simple preventive measures (Ninth Circuit).

Sony’s cross-petition addresses when ISP infringement qualifies as “willful” under 17 U.S.C. § 504(c). The Fourth Circuit held that knowledge of subscriber infringement suffices, while the Eighth Circuit requires evidence the ISP knew its own conduct was unlawful. This distinction has enormous practical impact—under the Fourth Circuit’s approach, the statutory damages ceiling automatically increases from $30,000 to $150,000 per work for contributory infringers. The Court has invited the Solicitor General to weigh in on both petitions — this will likely be submitted by the Trump Administration after January 20, 2025.

In King for Congress v. Griner, No. 24-321, the Court is presented with a circuit split regarding Rule 68 offers of judgment in copyright cases. The dispute involves the viral “Success Kid” meme, where a congressional campaign was found to be an innocent infringer (i.e., non-willful) yet sought to recover post-offer attorney’s fees under Rule 68. The Eighth Circuit joined the First, Seventh and Ninth Circuits in holding that copyright defendants cannot recover Rule 68 attorney’s fees because the Copyright Act limits fee awards to “prevailing parties.” Griner arguably won, but the total award was just $750.

Canadian Standards Association v. P.S. Knight Co., No. 24-537 asks whether privately-developed technical standards lose copyright protection when incorporated by reference into law. The Fifth Circuit, applying its prior decision in Veeck v. Southern Building Code Congress Int’l, Inc., 293 F.3d 791 (5th Cir. 2002), held that both the government edicts doctrine and merger doctrine strip such standards of protection, regardless of their private authorship. The petitioner argues this conflicts with Georgia v. Public.Resource.Org, Inc., 140 S. Ct. 1498 (2020), which emphasized that copyrightability turns on the identity of the author rather than whether content carries legal force. The case has significant implications for U.S. treaty obligations under the Berne Convention and the sustainability of private standards development, as many technical codes relied upon by federal agencies are created by organizations seeking copyright licensing revenue.

The dispute in BMC Software v. IBM, No. 24-569 arose when IBM used its IT outsourcing position to help customer AT&T replace BMC’s licensed mainframe software with IBM’s competing products—violating a license provision prohibiting IBM from using its access to “displace” BMC’s software. The Fifth Circuit reversed a $1.6 billion damages award, holding the license restriction was likely unenforceable as a restraint on trade because it could limit AT&T’s software choices. BMC argues this creates a circuit split with four courts of appeals that recognize software owners have a “presumptively valid business justification” for license restrictions. The case raises fundamental questions about the intersection of copyright and antitrust law, particularly regarding restrictions designed to prevent competitors from leveraging privileged access to unfairly compete.

Rutstein v. Compulife Software, No. 24-634 raises a novel trade secret issue: whether automated web scraping should be treated differently than manual data collection under the Defend Trade Secrets Act (DTSA). The Eleventh Circuit held that using automated tools to collect insurance premium quotes from Compulife’s public website constituted misappropriation by “improper means,” even though manually collecting the same data would be legal. Critics argue this creates an arbitrary distinction based on collection efficiency rather than the nature of information access. The case could provide crucial guidance on how trade secret law should adapt to automated data collection technologies that power much of the modern internet.

Finally, T-Mobile v. Simply Wireless, No. 24-637, presents a circuit split over maintaining common law trademark rights. The Fourth Circuit held that once rights are established through “extensive use,” they persist until abandoned under Section 45 of the Lanham Act, 15 U.S.C. § 1127—even during extended periods of non-use. This allowed Simply Wireless to pursue infringement claims against T-Mobile despite having made no use of its mark during multiple multi-year periods. This approach conflicts with other circuits requiring continuous use until alleged infringement begins. The case could resolve whether the continuous use requirement applies only to establishing common law rights or extends to maintaining them, with significant implications for dormant mark enforcement.

The Federal Circuit’s Divided Path on Divided Infringement

by Dennis Crouch

The Federal Circuit recently issued an important decision refining how courts should analyze infringement of system claims when multiple parties are involved in operating different components of the claimed system. This post looks at the court’s  new decision in CloudofChange, LLC v. NCR Corp., No. 23-1111 (Fed. Cir. Dec. 18, 2024) and contrasts it Centillion Data Systems, LLC v. Qwest Communications International, Inc., 631 F.3d 1279 (Fed. Cir. 2011).

These cases highlight a recurring challenge in patent law – how to analyze infringement when a claim requires components controlled by different actors. The issue is particularly salient for modern technology systems that often involve both vendor-operated backend servers and customer-operated frontend devices. (more…)

Recent Patent Cases at the Supreme Court

by Dennis Crouch

The Supreme Court has not granted certiorari in any patent cases this term. But the 2024 docket includes a number of important petitions -- some focusing on procedural issues and others on fundamental patent law questions. Here is a quick review of those currently pending before the high court:


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

DABUS AI Again Denied European Patent

by Dennis Crouch

The European Patent Office (EPO) has again rejected Dr. Stephen Thaler’s patent application that attempted to name his artificial intelligence system DABUS as an inventor.  The EPO examining division’s decision reinforces the foundational principle that inventors must be natural persons under European patent law. Article 81 of the European Patent Convention (EPC) requires a mandatory designation of inventor, and according a prior precedential decision that went against Thaler, the inventor “must be a natural person.” The examining division emphasized that this requirement stems from the interconnection between Article 81 EPC (designation of inventor) and Article 60(1) EPC (right to European patent).

Article 81: Designation of the inventor — The European patent application shall designate the inventor. If the applicant is not the inventor or is not the sole inventor, the designation shall contain a statement indicating the origin of the right to the European patent.

Article 60: Right to a European patent — (1) The right to a European patent shall belong to the inventor or his successor in title. . .

Of course, neither of these articles expressly state that the inventor must be human, but the implication from Article 60(1) in particular is that the inventor is someone with the capability of holding title. (more…)

Orange Book Device Patent Listings: Understanding Teva v. Amneal

by Dennis Crouch

In a major decision clarifying the scope of Orange Book patent listings, the Federal Circuit has ruled that device patents must claim at least the active ingredient to be properly listed. Teva Branded Pharm. Prods. R&D, Inc. v. Amneal Pharms. of N.Y., LLC, No. 24-1936, -- F.4th --, 2024 WL 2923018 (Fed. Cir. Dec. 20, 2024). The court rejected Teva's attempt to list patents covering only inhaler components, explaining that the listing statute requires patents to "claim the drug" - which means they must particularly point out and distinctly claim at least the active pharmaceutical ingredient.

[O]ur analysis of the numerous relevant statutory provisions and the relevant case law leads us to only one conclusion: To list a patent in the Orange Book, that patent must, among other things, claim the drug for which the applicant submitted the application and for which the application was approved. And to claim that drug, the patent must claim at least the active ingredient. Thus, patents claiming just the device components of the product approved in an NDA do not meet the listing requirement of claiming the drug for which the applicant submitted the application.

The dispute centers on five Teva patents related to components of its ProAir HFA albuterol inhaler - specifically the dose counter and canister features. After Amneal filed an Abbreviated New Drug Application (ANDA) seeking approval for a generic version, Teva sued for patent infringement, triggering an automatic 30-month stay of FDA approval. Amneal counterclaimed seeking delisting of the patents from the Orange Book, arguing they did not properly "claim the drug" as required by 21 U.S.C. § 355(b)(1)(A)(viii). The district court granted Amneal's motion for judgment on the pleadings, ordering Teva to delist the patents because they "contain no claim for the active ingredient at issue, albuterol sulfate" but instead "are directed to components of a metered inhaler device." Teva appealed, and the Federal Circuit stayed the delisting order pending its review. However, the appellate panel now affirmed the delisting order.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Federal Circuit Affirms $95 Million Verdict in E-Cigarette Patent Battle Between Altria and Reynolds

by Dennis Crouch

The Federal Circuit's December 19, 2024 decision in Altria (Philip Morris) v. R.J. Reynolds offers important guidance on patent damages methodology while potentially previewing issues soon to be addressed en banc in EcoFactor v. Google. The case centered on Reynolds' VUSE Alto e-cigarette product and its infringement of three Altria patents. U.S. Patent Nos. 10,299,517, 10,485,269, and 10,492,541.  While the court addressed multiple issues, I want to focus here on the damages analysis - particularly regarding comparable licenses and apportionment. Although the case is non-precedential, it includes both a majority opinion (authored by Judge Prost and joined by Judge Reyna) and a dissent (by Judge Bryson).  Like Judge Reyna's decision in EcoFactor, the case involves the use of lump-sum licenses to create a running royalty calculation, as well as the proper approach to apportioning damages so that the award is for the use of the patented invention.

The damages dispute focused primarily on how Altria's expert derived a 5.25% royalty rate from comparable license agreements, particularly a license between Fontem and Nu Mark. Under this agreement, Nu Mark paid Fontem a $43 million lump sum for rights to practice Fontem's patents through 2030. Following established precedent from Lucent Technologies, Inc. v. Gateway, Inc., 580 F.3d 1301 (Fed. Cir. 2009), Altria's expert analyzed Nu Mark's sales projections to convert this lump-sum payment into an effective royalty rate. The expert identified projections showing that a 5.25% royalty applied to sales from 2017 to 2023 would yield approximately $44 million in payments - close to the actual $43 million lump sum paid.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.